New York, USA - May 25, 2026 - By integrating computational design, ADMET property optimization, synthesis feasibility assessment, wet-lab validation, and pathology image analysis, the company offers a more connected and data-backed discovery workflow.
This integrated service is designed to help research teams prioritize candidate molecules, identify potential development risks earlier, and generate robust insights for preclinical decision-making.
Bridging the Gap Between In Silico Design and Wet-Lab Validation
At the heart of this enhancement is a seamless synergy between computational chemistry and laboratory validation. Creative Biolabs' closed-loop DMTA (Design-Make-Test-Analyze) workflow connects AI-based molecular generation with rigorous experimental testing. This approach supports more informed candidate prioritization by integrating AI-based prediction, multi-parameter optimization (MPO), and in-house validation assays.
"Our platform is designed to transition from automated molecular optimization to experimental confirmation more efficiently," said a senior scientist from Creative Biolabs' AI drug discovery team. "The goal is to balance activity, selectivity, and drug-likeness simultaneously to refine the lead optimization process."
Mitigating Risk Through Predictive ADMET Analysis
To address high attrition rates, Creative Biolabs has strengthened its AI-powered ADMET property optimization. Utilizing machine learning models trained on high-quality datasets, the service aims to assist in predicting absorption, distribution, metabolism, excretion, and toxicity endpoints more effectively than some traditional methods.
By identifying potential liabilities—such as drug-induced liver injury (DILI) or Ames mutagenicity—early in the pipeline, the workflow enables the proactive design of molecules with improved safety profiles. This predictive capability helps ensure that resources are focused on candidate molecules with the highest potential for successful preclinical development.
AI-Enabled Pathology Image Analysis for Preclinical and Translational Research
To further support the "Analyze and Validate" stages of the discovery cycle, Creative Biolabs offers AI-enabled pathology image analysis. This service complements molecular design by providing deep-learning-based insights for:
- Disease model characterization and evaluation.
- Biomarker quantification and discovery.
- Treatment response assessment and preclinical evidence generation.
By detecting morphological patterns and providing quantitative data, the platform assists researchers in interpreting complex biological responses during translational research.
FAQ: AI-Driven DMTA and ADMET Optimization
How does the AI optimize for multiple parameters? The platform uses multi-parameter optimization (MPO) to simultaneously balance potency with a comprehensive suite of ADMET properties, ensuring a well-rounded candidate profile.
What are the primary deliverables of this service? Clients receive a ranked candidate list, optimized molecular structures, detailed ADMET liability reports, and, where applicable, pathology image quantification data and in vitro validation results.
Who can benefit from this workflow? This service is tailored for biotech and pharma teams focused on lead optimization, ADMET/toxicology, and translational research who need to bridge the gap between computational design and wet-lab results.
Key Takeaways
Integrated Workflow: Connects AI design, synthesis feasibility, and biological testing.
Lead Optimization: Balances activity, selectivity, and ADMET properties through MPO.
Wet-Lab Validation: Confirms AI-designed candidates through in-house experimental assays.
Translational Insights: AI pathology supports biomarker quantification and disease model evaluation.
About Creative Biolabs
Creative Biolabs provides end-to-end support for the global biotechnology and pharmaceutical industries. From initial target identification to preclinical candidate selection, the company's multidisciplinary team combines biological expertise with AI technology to accelerate drug discovery pipelines.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://ai.creative-biolabs.com
